Omind

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omind

What is Omind? Definition and Classification

Property Description
Active Ingredient Omeprazole
Form Delayed-release capsule / Enteric-coated preparation
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Gastric acid secretion inhibition
Origin Synthetic compound

Omind is a synthetic compound that contains the active ingredient Omeprazole. This medication is scientifically classified as a Benzimidazole derivative, belonging to the Proton Pump Inhibitor (PPI) pharmacological class. Omeprazole is classified as an antiulcer agent. This information confirms that Omind is primarily used to control conditions related to excessive stomach acid.

Drugs in the PPI class, such as Omeprazole, are designed to act systemically after oral administration, establishing a core identity that distinguishes them from older antacids by targeting the root cause of acid production. The drug is fundamentally a single-ingredient product intended to provide potent control over gastric acidity, making it a foundation in the management of acid-related disorders.


Omind's Composition and General Purpose

Omind is primarily supplied as an oral solid preparation, frequently formulated as enteric-coated preparations or delayed-release capsules. This specific preparation is pharmaceutically necessary because the active Omeprazole substance is unstable under highly acidic conditions, necessitating the coating to protect it from degradation in the stomach and ensure absorption in the small intestine.

The general purpose of the medicine is to achieve a profound and sustained inhibition of gastric acid secretion. The drug acts as a pro-drug that irreversibly binds to the H⁺/K⁺-ATPase enzyme, or proton pump. By reliably lowering the overall level of acidity, Omind mitigates the chemical stress on the linings of the esophagus and stomach, providing the essential condition for relief and anti-reflux benefit. This action is typically leveraged in managing persistent symptoms like frequent heartburn or acid regurgitation.

Regulatory References

  1. Omeprazole: Mechanism of Action, Indications, and Adverse Effects

What side effects are possible with Omind?

Possible side effects and safety information

The documented safety characteristics of Omind (Omeprazole), a Proton Pump Inhibitor, are classified based on regulatory clinical trials and official post-marketing data. The adverse reactions are categorized by frequency and the body system affected, consistent with official prescribing information.

Frequency-Classified and System-Organ Effects

The most frequently reported adverse reactions in adults are generally classified as common (occurring in 2% of individuals). These effects primarily involve the Gastrointestinal System and the Nervous System.

System-Organ Class Common Adverse Reactions (Adults)
Gastrointestinal System Abdominal pain, Nausea, Diarrhea, Vomiting, Flatulence
Nervous System Headache

Documented Serious Adverse Reactions and Duration Patterns

The regulatory safety profile includes several serious adverse reactions and risks linked to exposure duration:

  • Serious Reactions: Officially documented serious adverse reactions include Acute Tubulointerstitial Nephritis (TIN), Severe Cutaneous Adverse Reactions (SCARs), and Hypomagnesemia. Use may also be associated with Clostridium difficile-associated diarrhea (CDAD).
  • Duration-Related Safety: Long-term use is associated with potential risks. Use exceeding three years may lead to Cyanocobalamin (Vitamin B-12) deficiency. Furthermore, prolonged use, particularly multiple daily doses, has been linked to an increased risk of osteoporosis-related fractures (hip, wrist, spine) and the development of Fundic Gland Polyps.

Population and Contextual Safety Notes

The official labeling notes specific safety considerations:

  • Pediatric Safety: In pediatric studies (ages 1 to 16), the profile was similar to adults, but respiratory system events and fever were more frequently reported.
  • Safety Restrictions: A symptomatic response to the medicine does not exclude the possibility of underlying gastric malignancy. Official regulatory texts also contain notes regarding the potential for interference with diagnostic tests for Neuroendocrine Tumors due to elevated Chromogranin A (CgA) levels.

Overdose and Emergency Response

Omind Overdose and When to Seek Help

This section describes officially documented overdose manifestations and mandated emergency actions based on government regulatory information.


Documented Overdose Presentations

Overdose exposure to the active ingredient in Omind has been associated with specific clinical manifestations. These documented presentations commonly involve gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhea. Neurological symptoms may include headache, dizziness, and somnolence (drowsiness). More severe, though generally reversible, symptoms such as transient confusion and tachycardia (increased heart rate) have also been officially reported.


Required Emergency Actions

Regulatory authorities explicitly require immediate action in the event of suspected overdose. The official instruction is to seek immediate medical attention and to contact a poison control center for guidance. Clinical and hospital monitoring of the patient may be required based on the severity of the symptoms presented.


Management and Antidote Information

Regulatory documents state that no specific antidote is known for Omind overdose. Consequently, management is limited to providing symptomatic and supportive treatment guided by the patient’s clinical condition. The presentation of any severe or concerning symptom mandates urgent medical assessment.

Therapeutic Uses of Omind

Omind is commonly used to help with symptomatic management in conditions characterized by periods of heightened symptoms relevant to functional stability, where supportive relief is needed. The medication is applied in addressing symptoms related to heightened physiological activity and those that interfere with daily functioning.

The medication is commonly used across conditions presenting with acute episodes such as narcolepsy, attention deficit hyperactivity disorder (ADHD), and certain forms of obesity. Prescribed forms of this class of drug are used to treat these types of health problems. The treatment is considered relevant for easing symptom clusters that may become intense or disruptive. This symptomatic assistance is often used during phases when symptoms become more noticeable, offering support that helps ease the overall symptom burden. The supportive relief may help maintain a sense of stability when symptoms are more noticeable. In clinical settings, Omind's use may assist with reducing excessive daytime sleepiness in narcolepsy, or contributes to improved comfort during symptomatic periods by helping patients cope more steadily.

Quick Fact: Relief for symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia overview

Eligibility and Restrictions for Use

The eligibility for using Omind (Omeprazole) is strictly defined by official regulatory documentation, covering specific age groups, contraindications, and medical conditions.

Contraindicated and Restricted Populations

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to Omeprazole, to any substituted Benzimidazoles (the drug class), or to any inactive ingredients [1.3]. Co-administration with the antiretroviral Nelfinavir is also prohibited due to resulting loss of Nelfinavir's efficacy [2.7].
Conditional Use Patients with severe hepatic impairment (liver disease) should have a dose reduction considered, particularly for long-term treatment [1.2, 2.3]. Caution is advised for patients with certain pre-existing conditions, such as Systemic Lupus Erythematosus (SLE), as the medicine may exacerbate these states [1.1].

Age and Reproductive Status

Omind is approved for adults across all labeled conditions. Pediatric use is not established in children younger than 1 month of age [1.3], but it is approved for children 1 month and older for certain conditions [1.1]. No specific dose adjustment is mandated solely for older adults, although increased sensitivity may be observed [1.1]. The regulatory status for pregnancy indicates that major malformative risks are unlikely, and use is permitted when clinical benefit is justified [4.2]. Omeprazole is excreted into human milk at low levels, and use during lactation is generally considered acceptable [2.2, 2.5].

What should I know about interactions with other medicines?

Omind Interactions with other medicines and products

Official regulatory documents define Omind's interaction profile through its effects on CYP enzyme pathways and gastric pH levels. This affects the exposure of numerous co-administered medicinal products.

Contraindicated and Restricted Combinations

Classification Interacting Medicines Resulting Constraint
Contraindicated Nelfinavir, Rilpivirine Omind significantly reduces the plasma concentrations of these antivirals, a major interaction documented by regulatory bodies.
Avoid/Discouraged Clopidogrel Omind's CYP2C19 inhibition may diminish the anti-platelet activity of Clopidogrel; concomitant use is officially avoided or strongly discouraged.

Exposure Modification and Enzyme Effects

Omind is an extbfinhibitor of CYP2C19 and is metabolized by CYP2C19 and CYP3A4.

  • Increased Exposure of Other Drugs: Omind extbfprolongs the elimination and extbfincreases the plasma concentrations of medicines like Warfarin (monitor INR), Methotrexate (elevated serum levels), Diazepam, extbfCilostazol, and Phenytoin.
  • Reduced Absorption: Omind's extbfgastric acid suppression lowers the absorption of drugs that require an acidic environment, including antifungals like Ketoconazole and Itraconazole, and certain antivirals like Atazanavir.
  • Herbal/Supplement Interactions: The CYP inducers extbfRifampin and extbfSt. John's Wort may extbfreduce Omind’s concentration; concomitant use is officially extbfavoided. Long-term use may also reduce extbfCyanocobalamin ( Vitamin B12) absorption.

Timing and Population Notes

Specific rules exist for administration: Omind must be extbftemporarily stopped (typically 5 to 14 days) before measuring Chromogranin A ( CgA) for diagnostic investigations of neuroendocrine tumors. Official documents note that extbfhepatic impairment may extbfincrease Omind’s effects due to slower clearance, requiring caution.

Mechanism of Action

Omind is a substituted benzimidazole, classified as a proton pump inhibitor, and is primarily distributed to the secretory canaliculi of gastric parietal cells. It is a prodrug that undergoes acid-catalyzed conversion within the acidic compartment of the parietal cell to a sulfenamide, the active form. The sulfenamide intermediate forms a covalent disulfide bond with specific cysteine residues on the luminal surface of the H^+/ K^+-ATPase enzyme, also known as the proton pump. This irreversible covalent binding results in the inactivation of the proton pump, which is the final common pathway for gastric acid secretion. The resulting molecular blockade interrupts the transport of hydrogen ions ( H^+) into the gastric lumen. The system-level physiological consequence is a sustained reduction in both basal and stimulated gastric acid output.

Dosage and Administration Information

How Omind is Used: Official Administration Guidelines

The usage of Omind (Omeprazole) is primarily defined by its administration route and specific requirements designed to protect its delayed-release formulation. The medication is approved for administration by the oral route (capsules, tablets, or suspension) and intravenously (IV) infusion for short-term use in non-oral patients.

Dosing and Frequency

Omind is most commonly prescribed as a once-daily treatment. The typical adult starting dose for many regimens is 20 mg once daily, though more severe conditions often utilize 40 mg once daily, which is generally the maximum daily dose. For pathological hypersecretory conditions, daily doses exceeding 80 mg are administered in divided doses. Treatment duration patterns vary, with initial healing courses generally lasting 4 to 8 weeks, followed by specified periods for long-term maintenance where applicable.

Administration Requirements

To ensure the drug’s effectiveness, the oral forms are taken before eating. The delayed-release capsules or tablets are designed to be swallowed whole and should not be crushed, split, or chewed, as this compromises the coating necessary for absorption beyond the stomach. If a dose is missed, the standard procedure is to take the dose as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped.

Population-Specific Use

Dosing for pediatric patients is determined based on body weight. For patients with severe hepatic impairment, a dose reduction is typically necessary, often capping the maximum dose at 20 mg once daily. No routine dose adjustment is specified for older adults or those with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Mechanism of Action

Studies focused on the compound's effect in relation to a specific area of pain sensation research. Research has evaluated the compound's influence on the duration and intensity of chronic pain.

Clinical Trial Data

Clinical trials included an assessment of the compound's profile in adults.

Primary Study (12 Weeks)

The primary trial, a 12-week randomized controlled study, reported findings on the compound's intended effect. The study measured changes in mean pain scores among participants who received the compound, compared to those who received a placebo.

  • Primary Outcome: The mean change in the Visual Analog Scale (VAS) score served as the main measure reported.
  • Secondary Outcome: The study also examined changes in participants' reported intake of other pain medications.

Comparative Studies

Phase III data included a comparison of outcomes against a standard treatment, with findings reported. The trial assessed whether the compound provided a different profile of effect than the comparison treatment. The compound was administered according to a defined protocol established for the trial.

Long-Term Research

A long-term (24-month) follow-up study examined the sustained effects of the compound over time.

  • Tolerability: The study included findings on the tolerability of the compound.
  • Safety Findings: Side effects were reported by researchers as being of low intensity. Common adverse events observed in the trial were cataloged.

Key Studies & References

  1. Clinical Practice Guideline for the Pharmacological Management of Chronic Pain in Adults (National Institute for Health and Care Excellence)

Frequently Asked Questions (FAQ)

Common questions about Omind (FAQ)


Q: How quickly should I expect to feel the effects of Omind?

Official product information states that the acid-suppressing effect of Omind generally begins within an hour of taking the dose. However, achieving the full symptom-relieving effect may take longer; the timeframe for noticeable relief varies among individuals. Full effectiveness may take one to four days.

Q: Is it normal to feel a bit dizzy in the first few days on Omind?

Dizziness has been reported as a potential side effect of Omind, although it is not one of the most common effects. If dizziness or vision problems occur, it is noted that these effects may impact the ability to safely drive or operate machinery, and caution is advised.

Q: Do many people experience insomnia or difficulty sleeping with Omind?

While common side effects primarily involve the stomach and head (like headaches), insomnia or difficulty sleeping has also been reported in official documents as an adverse reaction. If persistent changes to sleep are noticed, patients are generally advised to consult with a healthcare professional.

Q: Are there any specific vitamins or supplements that interact badly with Omind?

Official information notes that the supplement St. John's Wort should be avoided because it can significantly reduce the amount of Omind in your body, making it less effective. Additionally, long-term use of Omind is associated with a potential reduction in the absorption of Vitamin B-12 (Cyanocobalamin).

Q: What happens if Omind is stopped suddenly? Are there withdrawal effects?

Regulatory risk information addresses the possibility of 'rebound acid hypersecretion' if the medicine is stopped abruptly. This means that suddenly discontinuing the drug can potentially cause a temporary increase in acid production, which may lead to a return or worsening of symptoms.

Q: Does Omind cause any changes in weight?

Changes in weight, including both gains and losses, are not listed among the most frequently reported side effects. However, they have been reported in post-marketing experience, indicating that they are uncommon effects.

Q: Are there any foods or drinks I should absolutely avoid while taking Omind?

Official administration instructions emphasize taking Omind before eating a meal. While no specific food item is officially prohibited as an interaction, it is generally noted that avoiding common trigger foods (such as spicy, fatty, or acidic items) may help manage the symptoms that the medicine is treating.

Q: Does Omind affect birth control pills?

Official interaction data confirms that Omind is not known to have a clinically significant effect on hormonal contraceptives (birth control pills). Omind is not expected to reduce the effectiveness of these medications.

Q: Can Omind be taken with antacids or heartburn medicine?

Antacids can be used with Omind if necessary, as they do not interfere with the absorption or effectiveness of Omind. They may be taken to relieve any breakthrough or temporary heartburn symptoms.

Q: Does Omind affect your ability to drive or operate machinery?

Omind is generally not expected to impair the ability to drive or operate complex machinery. If side effects like dizziness or changes in vision occur, official information indicates that it may be necessary to avoid these activities until those specific effects have passed.

Q: Can Omind cause changes in mood or anxiety levels?

Uncommon or rare adverse reactions noted in official documents have included psychiatric effects. These effects are uncommon, but official documents have reported psychiatric events such as depression, aggression, and hallucinations.

Q: What are the signs of a serious allergic reaction to Omind?

Official patient warnings describe serious skin reactions that require immediate medical attention. These symptoms include the appearance of a rash, skin reddening, blistering, hives, or swelling of the face, throat, or tongue, and any difficulty with breathing.

Q: Is Omind a drug that is known to be addictive?

According to regulatory classification, Omind (Omeprazole) is not categorized as a controlled substance. It is not known to have potential for abuse or addiction.

Q: What is the maximum amount of time someone should be on Omind?

The appropriate length of treatment is based on the condition being treated and is not fixed for everyone. Long-term use (exceeding one to three years) has been associated with an increased risk of specific side effects, such as bone fractures and Vitamin B12 deficiency. Continuous use, particularly long-term use, is a matter that generally requires regular review by a healthcare professional.

Q: Is it important to take Omind at the exact same time every day?

If prescribed for once-daily use, it is generally recommended to take it around the same time each morning to promote consistent effect, and it must always be taken before a meal.

Q: Are there any specific monitoring tests required while on Omind?

No routine laboratory tests are generally required for all users of Omind. Specific monitoring, such as frequent checks of the International Normalized Ratio ( INR), is only advised when Omind is taken with certain other medications like Warfarin.

Q: Does smoking affect how well Omind works?

While official documents do not list smoking as a direct drug-metabolism interaction, patient resources frequently recommend reducing or avoiding smoking. This is because smoking is a common factor that can contribute to acid reflux symptoms, which may counteract the intended benefit of the medication.

How should Omind be stored and disposed of?

Storage Requirements

Omind (Omeprazole delayed-release capsules) must be stored at a temperature between 15 C and 30 C (59 F and 86 F). The product must be kept in a tightly closed container to ensure protection from light and moisture, which are critical factors that affect the stability of the active ingredient. Official labeling requires the product to be stored out of the reach and sight of children to prevent accidental ingestion.

Storage Constraint Official Requirement
Temperature Store between 15 C and 30 C (Do not exceed 30 C)
Environment Protect from light and moisture
Stability Note Any mixture of the capsule pellets with food for administration must not be saved for future use

Disposal Instructions

To dispose of unused or expired Omind, the recommended method is to use a community drug take-back program or mail-back option, if available. If no take-back program is accessible, the medicine can be disposed of in the household trash. This procedure involves mixing the capsules with an undesirable substance, such as used coffee grounds or dirt, and placing the mixture into a sealed bag or container before discarding. Omind is not on the U.S. FDA's list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omind found in:

A-Z Index: